



## Ziopharm Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference

December 21, 2018

BOSTON, Dec. 21, 2018 (GLOBE NEWSWIRE) -- [Ziopharm Oncology](#), Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 37<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2019, at 9 a.m. PST.

To access a live audio webcast of the presentation, please visit the Investor Relations section at [www.ziopharm.com](http://www.ziopharm.com).

### **About Ziopharm Oncology, Inc.**

Ziopharm Oncology is an immuno-oncology company focused on developing end-to-end cost-effective solutions using its non-viral *Sleeping Beauty* platform for TCR and CAR T-cell therapy and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The *Sleeping Beauty* platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's very rapid T-cell manufacturing process. The *Sleeping Beauty* platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform or Ad-RTS-hIL-12 plus veledimex as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including a collaboration with Regeneron Pharmaceuticals.

### Company contacts:

David Connolly

Vice President, Corporate Communications and Investor Relations

617-502-1881

[dconnolly@ziopharm.com](mailto:dconnolly@ziopharm.com)

Mike Moyer

Vice President, Portfolio Strategy

617-765-3770

[mmoyer@ziopharm.com](mailto:mmoyer@ziopharm.com)



Source: ZIOPHARM Oncology Inc